Loading…
Loading…
There's no shortage of stocks that provide risk-tolerant traders with excitement. Plenty of ETFs accomplish that objective, too.
KORU Medical Systems is transforming into a digitally enabled drug delivery platform, leveraging secular tailwinds in at-home subcutaneous infusion therapies. Q2 revenue grew 18.2% to $12.05M with positive net income and gross margin expansion to 65.1%, driven by domestic core strength and international growth. International ramp is slower than forecast, prompting narrowed FY guidance to $47.5M–$48.5M revenue and a raised gross margin outlook to 62%–64%.
The Direxion Daily MSCI South Korea Bull 3X ETF (KORU) has fallen 73% from its highs while the KOSPI dropped 38%, even though SK Hynix's operating profit grew 500% in the same period. The KOSPI's forward P/E fell to 4.5x and its earning yield rose to 22%, driven mainly by forced margin call liquidations rather than weaker earnings. FLKR's daily RSI has already shown a V-shaped recovery near the 30 level, signaling renewed demand interest despite KORU's 3x leverage risks.
KORU Medical Systems NASDAQ: KRMD reported second-quarter revenue of $12 million, up 18% from a year earlier, as domestic patient starts, market-share gains and international demand supported growth. The company also said it achieved positive net income for the first time since 2019 and raised its full-year gross-margin outlook, while narrowing revenue guidance because certain international prefilled-syringe market launches are taking longer to develop than expected.
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2026. The Company also updated guidance for the full year 2026. Second Quarter 2026 and Recent Highlights Net revenues grew 18% over the p.
South Korea's AI and semiconductor strength remains compelling despite recent volatility. Here's how investors can play the opportunity with ETFs.
I have a sell rating on Direxion Daily MSCI South Korea Bull 3X ETF due to technical weakness and high volatility. KORU is closely tied to EWY, which is dominated by SK Hynix and Samsung, and faces bearish technical patterns and seasonally weak August–October trends. Despite EWY's low P/E and high EPS growth, cyclical risks in semiconductors and negative compounding in leveraged ETFs warrant caution.
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2026 financial results on Wednesday, August 5, 2026. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discus.